A proposed Entyvio biosimilar for under-the-skin use gets FDA review
Alvotech (ALVO) announced FDA acceptance of its Biologics License Application for AVT80, a proposed biosimilar to Entyvio (vedolizumab) for subcutaneous use. The application is supported by clinical data showing AVT80 met primary endpoints. Alvotech and Teva are partnering, with Alvotech handling development and Teva commercialization. AVT80 and AVT16 (for intravenous use) are investigational and not yet approved.
How this was made
The 30-second read
Why it matters
Regulatory acceptance signals progress toward market launch, likely boosting investor confidence and stock price.
Market read
First report of FDA BLA acceptance for a subcutaneous biosimilar, a material event for Alvotech and the broader biosimilars market.
What to watch
Potential competition from other biosimilars and pricing pressures could temper market reaction.
Background
Alvotech announced FDA acceptance for review of its AVT80 biosimilar in subcutaneous format, expanding its vedolizumab program alongside AVT16.
Ticker impact
FDA accepted for review the BLA for Alvotech's AVT80 subcutaneous biosimilar to Entyvio.
Potential short-term upside of 10‑15% if approval follows.
FDA acceptance is a key step; biotech peers typically rally on similar news.
Market effects
Strengthens the biosimilars sector outlook, may boost peers developing vedolizumab biosimilars.
Highlights Icelandic biotech Alvotech's US market entry, could attract regional investors.
Adds to global pipeline of affordable biologics, relevant for worldwide healthcare spend.
Counterpoint
Approval is not guaranteed; FDA may request additional data, limiting upside.
Key entities
- companyAlvotech
Icelandic biotech developing biosimilars, ticker ALVO.
- companyTeva Pharmaceutical Industries
Partner responsible for commercialization of AVT80.
